Advertisement

Akuter Herzinfarkt im Zeitalter von Lyse und Akut-PTCA: Hat sich die Bedeutung der β-Blocker-Therapie geändert?

  • H. Schneider
  • F. Weber
  • C. Nienaber

Zusammenfassung

Die Bedingungen für eine optimale Akuttherapie des Myokardinfarkts sowie eine erfolgreiche Primär- und Sekundärprävention der KHK sind im deutschsprachigen Raum prinzipiell flächendeckend vorhanden. Im 11-jährigen Verlaufszeitraum des MONICA-Herzinfarktregisters Augsburg (1985 – 1995) konnte eine Abnahme der Herzinfarktinzidenz und -mortalität für Männer und postmenopausale Frauen um etwa 20% (p < 0,001) im Vergleich zur vorherigen Dekade verzeichnet werden. Mit Verkürzung der Prähospitalzeit und Einführung verbesserter therapeutischer Strategien wurden die Dauer des Krankenhausaufenthalts verkürzt und die 30 Tage-Letalität von 12 auf 8% gesenkt [22].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ambrosioni E, Borghi C, Magnani B (1995) The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332: 80–85PubMedCrossRefGoogle Scholar
  2. 2.
    Arnout J, Simoons M, DeBono D et al. (1992) Correlation between level of heparinization and patency of the infarct related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 20: 513–519PubMedCrossRefGoogle Scholar
  3. 3.
    Arntz HR, Tebbe U, Schuster HP et al. (2000) Leitlinien zur Diagnostik and Therapie des akuten Herzinfarktes. Z Kardiol 89: 364–374CrossRefGoogle Scholar
  4. 4.
    Brener SJ, Barr LA, Burchenal JE et al. for ReoPro and Primary PTCA Organisation and Randomized Trial (RAPPORT) Investigators (1997) Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Lancet 349: 1422–1428CrossRefGoogle Scholar
  5. 5.
    Cannon PC, Weintraub WS, Demopoulus LA et al. for the TACTICS-Thrombolysis in Myocardial Infarction 18 Investigators (2001) Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IITa inhibitor tirofiban. N Engl J Med 344: 1879–1887PubMedCrossRefGoogle Scholar
  6. 6.
    CAPRIE Steering Committee (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348: 1329–1339CrossRefGoogle Scholar
  7. 7.
    Chadda K, Goldstein S, Byington R, Curb JD (1986) Effect of propanolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73: 503–510PubMedCrossRefGoogle Scholar
  8. 8.
    CIBIS II Investigators group (1999) The cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet 353: 9–13CrossRefGoogle Scholar
  9. 9.
    Dargie H, Colucci W, Ford I et al. for the CAPRICORN Investigators (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 357: 1385–1390PubMedCrossRefGoogle Scholar
  10. 10.
    FRISC II Investigators Group (1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Fragmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Lancet 354: 708–715CrossRefGoogle Scholar
  11. 11.
    Gawaz MP (1999) Das Blutplättchen. Thieme, Stuttgart New York, pp 89–101Google Scholar
  12. 12.
    GISSI 1 Collaborative Group (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1: 397–402Google Scholar
  13. 13.
    Granger CG, Califf RM (1995) Stabilizing the unstable artery. In: Califf RM et al. (eds) Acute coronary care, 2nd ed Mosby-Year Book, St Louis, pp 525–541Google Scholar
  14. 14.
    Grobecker HF, Krämer BK (1996) Beta-Rezeptoren-Antagonisten. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S 38–39Google Scholar
  15. 15.
    Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico: GISSI 3 (1994) Effect of lisinopril and transdermal glyceryl trinitrat singly and together on a 6-week mortality and ventricular function after myocardial function. Lancet 343: 1115–1122Google Scholar
  16. 16.
    GUSTO II b Angioplasty Substudy Investigators (1997) A clinical trial comparison primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The global use of strategies to open occluded coronary arteries in acute coronary syndromes. N Engl J Med 336: 1621–1628CrossRefGoogle Scholar
  17. 17.
    Heinrath KM, Werdan K (1999) Medikamentöse Therapie mit ß-Blocken. In: Griebenow R, Gülker H, Dominiak P et al. (Hrsg) Autonomes Nervensystem and koronare Herzerkrankung. Novartis Pharma, Nürnberg, S 237–294Google Scholar
  18. 18.
    ISIS 1 (First International Study of Infarct Survival) Collaborative Group (1986) Randomised trial of intravenous atenolol among 16077 cases of suspected acute myocardial infarction. Lancet 2: 57–66Google Scholar
  19. 19.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 18187 cases of suspected acute myocardial infarction. Lancet 2: 349–360Google Scholar
  20. 20.
    ISIS-4 collaborative group (1991) Fourth international study of infarction survival: protocol for a large simple study of effect of oral mononitrate, of oral captopril, and of intravenous magnesium. Am J Cardiol 68: 87D - 100DCrossRefGoogle Scholar
  21. 21.
    Louis A, Cleland JG, Crabbe Set al. (2001) Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientic Sessions of the ACC 2001. Eur J Heart Fail 3: 381–387PubMedCrossRefGoogle Scholar
  22. 22.
    Löwel H, Engel S, Hörmann A et al. (2000) Akuter Myokardinfarkt aus epidemiologischer Sicht. In: Arntz HR, Schuster HP (Hrsg) Die Notfalltherapie bei akutem Myokardinfarkt. Steinkopff, Darmstadt, S 13–23CrossRefGoogle Scholar
  23. 23.
    MERIT-HF Investigators Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353: 2001–2007CrossRefGoogle Scholar
  24. 24.
    Mitka M (2001) Results of CURE trial for acute coronary syndrome. JAMA 285: 1828–1829PubMedCrossRefGoogle Scholar
  25. 25.
    Montalescot G, Barragan P, Wittenberg O et al. for the Admiral Investigators (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344: 1895–1903PubMedCrossRefGoogle Scholar
  26. 26.
    Neumann FJ, Blasini R, Schmitt C et al. (1998) Effect of glycoprotein IIb/IIIa blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98: 2695–2701PubMedGoogle Scholar
  27. 27.
    Packer M, Coats AJS, Fowler MB et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658PubMedCrossRefGoogle Scholar
  28. 28.
    Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327: 669–677PubMedCrossRefGoogle Scholar
  29. 29.
    Roux S, Christeller S, Lüdin E (1992) Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a metaanalysis. J Am Coll Cardiol 19: 671–677PubMedCrossRefGoogle Scholar
  30. 30.
    Ryan TJ, Antman EM, Brooks NH et al. (1990) ACC/AHA guidelines for the management of patient with acute myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 31: 1016–1030Google Scholar
  31. 31.
    Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 334: 1383–1389Google Scholar
  32. 32.
    Schömig A, Kastrati A, Dirschinger J et al. for the Stent versus Thrombolysis for Occluded Coronary Arteries in Patient with Acute Myokardial Infarction Study Investigators (2000) Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 343: 385–391CrossRefGoogle Scholar
  33. 33.
    Schwartz L, Bourassa MG, Lesperance J et al. (1988) Aspirin and dipyridamol in the prevention of restenosis after PTCA. N Engl J Med 318: 1714–1719PubMedCrossRefGoogle Scholar
  34. 34.
    Statistisches Bundesamt Gesundheitswesen (1999) Fachserie 12, Reihe 4 Todesursachen 1997. Statistisches Bundesamt, WiesbadenGoogle Scholar
  35. 35.
    Swedberg K, Held P, Kjekshus J et al. (1992) Effect of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327: 678–684PubMedCrossRefGoogle Scholar
  36. 36.
    The Acute Infarction Ramipril Efficacy Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821–828Google Scholar
  37. 37.
    The GUSTO I Investigators (1993) An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673–682CrossRefGoogle Scholar
  38. 38.
    TIMI Study Group (1989) Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) phase II trial. Eur Heart J 6: 618–627Google Scholar
  39. 39.
    Topol EJ, Califf RM, Van de Werf F et al. for the GUSTO V Investigators (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357: 1905–1914PubMedCrossRefGoogle Scholar
  40. 40.
    Weaver WD, Simes RJ, Betriu A et al. (1997) Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 278: 2093–2098PubMedCrossRefGoogle Scholar
  41. 41.
    Weis, AC, Gulba DC (1999) Thrombolysetherapie des akuten Myokardinfarktes and adjuvante Therapien. In: Griebenow R, Gülker H, Dominiak P et al. (Hrsg.) Autonomes Nervensystem and koronare Herzerkrankung. Novartis Pharma, Nürnberg, S 138–150Google Scholar
  42. 42.
    Witthaut R, Werdan K (1998) Neue Aspekte der Therapie des akuten Myokardinfarktes für den Notarzt. Intensiv-Notfallbehandlung 23: 107–118Google Scholar
  43. 43.
    Yusuf S, Peto R, Lewis Jet al. (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335–371PubMedCrossRefGoogle Scholar
  44. 44.
    Yusuf S, Wittes J, Friedman J (1988) Overview of results of randomized clinical trials in heart disease. Treatments following myocardial infarction. JAMA 260: 2088–2093PubMedCrossRefGoogle Scholar
  45. 45.
    Zijlstra F, Hoorntje JC, de Boer MJ et al. (1999) Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 341: 1413–1419PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2001

Authors and Affiliations

  • H. Schneider
    • 1
  • F. Weber
    • 1
  • C. Nienaber
    • 2
  1. 1.Klinik und Poliklinik für Innere Medizin, Abteilung KardiologieUniversität RostockDeutschland
  2. 2.Abteilung Kardiologie Klinik und Poliklinik für Innere MedizinUniversität RostockRostockDeutschland

Personalised recommendations